NCT02621164View on ClinicalTrials.gov

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

454

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

June 30, 2015

Conditions
Influenza, Human
Interventions
BIOLOGICAL

NBP607-QIV

For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)

BIOLOGICAL

Agrippal S1

For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02621164 - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents | Biotech Hunter | Biotech Hunter